Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.08 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.11 | 2.17 | 1.10 | 1.34 | 0.82 | 3.02 | 4.67 | 3.54 | 3.48 | 0.97 | 0.85 | 0.93 | 0.39 |
| — | -28.3% | -76.5% | -62.2% | -76.4% | +212.0% | +450.1% | +282.2% | +782.7% | +11.9% | -25.2% | -69.9% | -86.9% | |
| P/B Ratio | 1.72 | — | — | — | 23.69 | 6.80 | 8.24 | 3.12 | 3.96 | 0.68 | 0.62 | 0.50 | 0.36 |
| — | — | — | — | +497.5% | +901.9% | +1230.3% | +528.0% | +1001.4% | +59.7% | +42.7% | -56.1% | -64.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CASI Pharmaceuticals, Inc.'s operating margin was -347.2% in Q3 2025, down 80.8 pp QoQ and down 238.6 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -219.2% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 55.8% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.1% | 23.0% | 49.3% | 58.0% | 24.2% | 51.9% | 51.9% | 53.0% | 59.0% | 58.7% | 59.4% | 59.5% | 72.0% |
| — | -55.8% | -5.1% | +9.5% | -59.1% | -11.6% | -12.6% | -11.0% | -18.0% | +0.5% | +1.4% | +1.7% | +23.1% | |
| Operating Margin | -138.8% | -347.2% | -266.5% | -166.3% | -96.7% | -108.6% | -220.9% | -270.4% | -68.9% | -57.6% | -81.9% | -86.4% | -82.8% |
| — | -219.7% | -20.6% | +38.5% | -40.4% | -88.4% | -169.8% | -212.9% | +16.9% | -3.0% | -9.8% | -12.6% | +31.3% | |
| Net Margin | -137.6% | -353.9% | -320.4% | -172.3% | -107.6% | -107.7% | -175.0% | -279.5% | -88.1% | -52.4% | -104.3% | -72.0% | -128.0% |
| — | -228.5% | -83.0% | +38.4% | -22.1% | -105.4% | -67.9% | -288.2% | +31.2% | -3.0% | -16.4% | +24.1% | -109.3% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -301.8% | — | — | — | -183.1% | -73.4% | -56.9% | -48.1% | -16.2% | -8.9% | -17.6% | -9.3% | -26.0% |
| — | — | — | — | -1027.8% | -725.9% | -222.4% | -416.7% | +37.6% | -47.7% | -116.3% | -11.9% | -405.2% | |
| ROA | -60.9% | -39.1% | -37.1% | -22.8% | -24.5% | -14.6% | -12.7% | -14.3% | -8.1% | -6.1% | -12.3% | -6.5% | -17.4% |
| — | -167.6% | -191.4% | -59.1% | -202.5% | -139.8% | -3.5% | -119.7% | +53.5% | -44.6% | -99.2% | -1.4% | -327.3% | |
| ROIC | -153.0% | — | — | -154.9% | -71.9% | -36.9% | -33.1% | -27.6% | -12.1% | -11.3% | -14.6% | -16.2% | -23.1% |
| — | — | — | -462.1% | -494.9% | -225.6% | -126.8% | -70.2% | +47.6% | -78.1% | -120.9% | -125.0% | -86.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 90.6% YoY to 0.30x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 11.96 | — | — | — | 11.96 | 1.38 | 2.05 | 1.20 | 0.88 | — | — | — | 0.02 |
| — | — | — | — | +1261.0% | — | — | — | +4277.1% | — | — | — | -50.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.09 | 0.30 | 0.48 | 0.81 | 1.09 | 3.20 | 3.88 | 5.05 | 3.55 | 4.91 | 5.12 | 4.74 | 4.32 |
| — | -90.6% | -87.6% | -84.0% | -69.4% | -34.9% | -24.2% | +6.5% | -17.8% | +162.9% | +59.6% | +24.9% | -8.1% | |
| Quick Ratio | 0.94 | 0.24 | 0.39 | 0.68 | 0.94 | 2.32 | 2.36 | 3.25 | 2.60 | 4.17 | 4.47 | 4.13 | 3.96 |
| — | -89.8% | -83.4% | -79.0% | -63.8% | -44.3% | -47.3% | -21.5% | -34.3% | +148.7% | +61.4% | +17.1% | -13.1% | |
| Interest Coverage | -45.49 | -54.75 | -45.59 | -52.69 | — | -138.75 | -159.80 | -48.02 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCASI Pharmaceuticals, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CASI Pharmaceuticals, Inc.'s current operating margin is -138.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CASI Pharmaceuticals, Inc.'s business trajectory between earnings reports.